Type 2 diabetes and hypertension. Famous duets in medicine Review article
Article Sidebar
Main Article Content
Abstract
The importance of hypertension treatment has expanded beyond blood pressure management to include additional risk factors, mainly diabetes. A number of studies have shown that telmisartan has partial PPAR-γ-agonist activity. Telmisartan is one of the preferred choices of antihypertensive in patients of diabetes with hypertension. Telmisartan is effective in lowering BP and improving metabolic parameters in patients of T2DM with or without complication.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Asmar R, Gosse P, Topouchian J et al. Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst. 2002; 3(3): 176-80.
3. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005; 4: 6.
4. Wienen W, Enthzerod M, van Meel JCA et al. A review on telmisartan: a novel, long-acting aniotensin II-receptor antagonist. Cardiovasc Ther. 2000; 18(2): 127-56.
5. Derosa G, Ragonesi PD, Mugellini A et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004; 27(7): 457-64.
6. Schmieder RE, Delles C, Mimran A et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007; 30: 1351-6.
7. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological aspects and clinical applications. Eur Heart J. 2006; 27(1): 2588-605.
8. Derosa G, Cicero AFG, Bertone G et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid prolife in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther. 2004; 26(8): 1228-36.
9. Galzerano D, Tammaro P, del Viscovo L et al. Three-dimensional echocardiografic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens. 2005; 18: 1563-9.
10. Petrovic J, Petrovic D, Vukovic N et al. Ventricular and vascular remodeling – effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res. 2005; 33(suppl 1): 39A-49A.
11. Okin P, Wachtell K, Devereux RB et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006; 296: 1242-8.
12. The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-59.
13. Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022-31.
14. Barnett AH, Bain SC, Bouter P et al; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351: 952-1961.
15. Bakris G, Burgess E, Weir M et al; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008; 74: 364-9.